40 results about "Platinum chemotherapy" patented technology

Provided herein are compositions that contain a nanoparticle containing a plurality of polymers, wherein at least a fraction of the polymers comprise a hydrophobic polymer, a topoisomerase inhibitor, and a Pt-containing chemotherapeutic agent, where the polymers self-assemble in an aqueous liquid to form the nanoparticle, and where the Pt-containing chemotherapeutic agent and the topoisomerase inhibitor are present within the hydrophobic core of the nanoparticle in a ratio of between about 24:1 to about 1:24. Also provided are methods of reducing the proliferation of a cancer cell and methods of treating cancer in a subject that include the use of these compositions. Also provided are methods of making these nanoparticles.

The invention relates to application of miRNA in preparation of a diagnostic reagent for predicting platinum chemotherapy drug resistance of high-grade serous ovarian cancer. The miRNA comprises miR-1287, miR-3131, miR-335, miR-4419, miR-4468 and miR-96. The invention also provides application for analyzing and detecting platinum chemotherapy drug resistance of high-grade serous ovarian cancer onthe basis of the determination of the expression quantity of miR-1287, miR-3131, miR-335, miR-4419, miR-4468 and miR-96, and the application has better accuracy than the existing method for predictingplatinum chemotherapy drug resistance of high-grade serous ovarian cancer.

Systems and methods for determining whether a cancer patient may respond to PARP inhibitor and/or platinum chemotherapy based on identifying exon excision variants in the BRCA 1 gene are provided. Exon excision variants may encode a hypomorphic BRCA1 protein. The cancer patient may be a breast cancer patient or an ovarian cancer patient. The patient may have any cancer in which exon deficiency in the BRCA1 gene contributes to resistance to PARP inhibitor or platinum therapy.

The invention relates to the technical field of medicine and relates to a use of cis-platinum and particularly relates to a use of cis-platinum in high-level granulocyte-like myeloid derived suppressor cell (G-MDSC) bladder cancer treatment and a treatment method. In-vitro experiment and in-vivo animal experiment results show that the amount of G-MDSC in a bladder cancer focus is significantly increased than that of G-MDSC in a paracancerous control group and the amount of CD8+T in a bladder cancer focus is reduced than that of CD8+T in the control group so that an immunosuppressive microenvironment is induced and formed and the establishment and growth of bladder cancer are promoted. The cis-platinum chemotherapy can significantly inhibit the progress of bladder cancer caused by abnormal increasing of G-MDSC and can be further used for high level G-MDSC bladder cancer treatment.

The invention relates to a long non-coding RNA (lnc RNA) model capable of predicting recurrence of gastric cancer and response to platinum drugs. The model comprises lnc RNA sequences as shown in SEQ ID No.1-11, and the expression quantities of the lnc RNA sequences are associated with the recurrence of patients with gastric cancer. The invention also relates to a construction method of the lnc RNA model capable of predicting recurrence of gastric cancer and response to platinum drugs. The construction method comprises the following steps: 1, carrying out correlation analysis; 2, determining an importance degree; 3, calculating relapse free survival (RFS) risk index of a patient; 4, judging the risk; 5, predicting effectiveness evaluation; 6, carrying out effect verification. The lnc RNA model not only can predict and divide high and low risk groups for prognosis of the patients with gastric cancer, but can also predict the sensitivity of the patients to platinum chemotherapy, thus reducing overtreatment.

The invention belongs to the fields of medical molecular genetics and clinical medicine, and particularly relates to a molecular marker and a kit for predicting the clinical benefit rate and the progression-free survival of platinum-containing chemotherapy for later-period non-small cell lung cancer. The molecular marker comprises an RICTOR gene related to the clinical benefit rate and the progression-free survival of the platinum-containing chemotherapy for the later-period non-small cell lung cancer (NSCLC), and comprises a single-nucleotide polymorphism site rs6878291 on the gene. As an application of the molecular marker, the invention also provides the RICTOR gene polymorphism detection kit for an NSCLC patient prognostic the platinum-containing chemotherapy. The medical molecular and the kit can be used for predicting the clinical benefit rate and the progression-free survival of the platinum-containing chemotherapy for the later-period non-small cell lung cancer, and provides bases for individualized treatment of patients with the disease.

The invention belongs to the technical field of medical molecular genetics and clinical medicine and particularly discloses a molecular marker for predicting the curative effect of platinum chemo-treatment on later non-small cell lung cancer and an application thereof. The molecular marker comprises an ABCB11 gene and mononucleotide polymorphic sites rs12692889 on the ABCB11 gene, wherein the ABCB11 gene is relevant to the curative effect of the platinum chemo-treatment on the later non-small cell lung cancer. As an application of the molecular marker, the invention also provides an ABCB11 gene polymorphism detection kit used for predicting the curative effect of the platinum chemo-treatment on non-small cell lung cancer (NSCLC) patients. The molecular marker and the detection kit can be used for detecting or predicting the curative effect of the platinum chemo-treatment on later non-small cell lung cancer patients, so the basis is provided for the realization of the individual chemo-treatment of the patients.

The invention discloses an application method of a circular RNA CircSERPINE2 and a detection and treatment preparation. The invention relates to a detection reagent for detecting ovarian cancer platinum chemotherapy tolerance, and in particular relates to a kit for detecting whether ovarian cancer is tolerant to platinum drugs or not by a real-time fluorescence quantitative analysis method and a human ovarian cancer platinum tolerance treatment preparation. Researches prove that the CircSERPINE2 is highly expressed in the platinum-resistant ovarian cancer tissue, and the CircSERPINE2 is a marker of the platinum resistance of the ovarian cancer, so that the CircSERPINE2 expression is applied to the detection of the platinum chemotherapy resistance of the ovarian cancer and the enhancement of the chemotherapy sensitivity of the human ovarian cancer platinum drugs through inhibition, and the CircSERPINE2 expression has profound clinical significance and generalization performance.

The invention discloses a black phosphorus nanosheet/gold nanoparticle composite material and a preparation method and application thereof. In the black phosphorus nanosheet/gold nanoparticle composite material, the mass percentage of the black phosphorus nanosheet is greater than or equal to 16.7%, a gold nanoparticle solution is added into dispersion liquid including the black phosphorus nanosheet, and thus the black phosphorus nanosheet/gold nanoparticle composite material can be obtained through ultrasonic oscillation. The black phosphorus nanosheet/gold nanoparticle composite material provided by the invention can efficiently load cis-platinum chemotherapeutic drugs, can realize photo-thermal, photodynamic and chemotherapeutic combined treatment on oral squamous cell carcinoma, and has excellent treatment effect.

The present disclosure relates gold carbene naphthoquinone compounds and salts thereof. In some aspects, these compounds can be used to treat cancer including cancers which are resistant to one or more other chemotherapeutic agents such as cisplatin or platinum chemotherapeutic agents. Also provided herein are pharmaceutical compositions comprising the gold carbene naphthoquinone compounds.

The invention discloses an application method of long-chain non-coding RNA LOC107987064, a detection preparation and a treatment preparation. The invention relates to a detection reagent for detecting ovarian cancer platinum chemotherapy tolerance, in particular to a kit for detecting whether ovarian cancer is tolerant to platinum drugs or not by a real-time fluorescence quantitative analysis method and a human ovarian cancer platinum tolerance treatment preparation. The researches prove that the LncRNA LOC107987064 is highly expressed in a platinum-resistant ovarian cancer tissue, and the LOC107987064 is a marker of the platinum resistance of the ovarian cancer, so that the expression of the LOC107987064 is applied to the detection of the platinum chemotherapy resistance of the ovarian cancer and the enhancement of the chemotherapy sensitivity of the human ovarian cancer platinum drugs through inhibition, and the LncRNA LOC107987064 has profound clinical significance and generalization performance.

The invention relates to application of apolipoprotein ApoA1 in detection of drug resistance of cervical cancer to platinum chemotherapy, and the research of the invention defines that the apolipoprotein ApoA1 can be used as a cervical cancer platinum chemotherapy drug resistance marker, and regulates and controls an MAPK signal channel through STAT1 to promote cell proliferation so as to cause the chemotherapy resistance of platinum drugs.

The invention provides an application of a polymer in cis-platinum detoxification. The polymer as shown in the formula (1) provided by the invention is used as a nano antidote, can circulate and enrich in vivo and has responsiveness to different physiological environments, the removal efficiency of cis-platinum in normal tissues is improved, and different microenvironments of tumor tissues and the normal tissues are utilized to improve the removal efficiency of cis-platinum in the normal tissues. The selectivity of the polymer nano antidote in the formula (1) combined with cis-platinum can be further improved, and the damage to the liver and the kidney in the cis-platinum chemotherapy process is reduced, so that the aim of improving the chemotherapy tolerance of tumor patients on the premise of ensuring the treatment effect is achieved.

The invention relates to a kit for diagnosing and treating malignant female germ cell tumors. The kit comprises a detection reagent for OVOL2 expression level and a cis-platinum drug for chemotherapy. By adopting the kit for diagnosing and treating the female malignant germ cell tumor, the sensitivity degree of the female malignant germ cell tumor to cis-platinum chemotherapy can be predicted in advance, so that a treatment scheme is optimized, unnecessary chemotherapy is reduced, and the prognosis of a patient is improved while the life quality of the patient is improved.

The invention discloses an in-situ gelling chemotherapy immune pharmaceutical composition, which comprises a first composition, a second composition and a third composition, the first composition comprises a fat-soluble immunologic adjuvant and a surfactant, the second composition comprises a carboxylic acid ligand-containing platinum chemotherapy drug capable of causing immunogenic death and a protective filler, and the third composition comprises a carboxylic acid ligand-containing platinum chemotherapy drug capable of causing immunogenic death and a carboxylic acid ligand-containing platinum chemotherapy drug capable of causing immunogenic death and a carboxylic acid ligand-containing platinum chemotherapy drug capable of causing immunogenic death. The third composition is prepared from soluble alginate, a protective filling agent and a pH (Potential of Hydrogen) regulator. The invention provides a composition with better stability, which can better generate a synergistic anticancer effect, reduce side effects, reduce the metastasis probability and recurrence probability of cancers, and inhibit the growth of distal metastatic tumors and reduce the recurrence probability of tumors through immunoreaction while effectively killing in-situ tumors. The invention further discloses a preparation method of the in-situ gelling chemotherapy immune composition, and the product system is good in stability and easy to store for a long time.

In order to solve the problem of clinical platinum chemotherapy drug resistance of non small cell lung cancer (NSCLC) at present, the invention provides application of a target site enhancer of rs2280496 or rs189178649 in preparation of a platinum chemotherapy sensitization drug for treating NSCLC, and further, the platinum chemotherapy sensitization drug is cis-platinum. The target site enhancercan be used as a novel therapeutic drug for overcoming platinum chemotherapy drug resistance.

The invention discloses an application method of long-chain non-coding RNA LOC730101 and a detection and treatment preparation. The invention relates to a detection reagent for detecting the sensitivity of ovarian cancer platinum chemotherapy, in particular to a kit for detecting whether ovarian cancer is sensitive to platinum drugs or not by a real-time fluorescence quantitative analysis method and a human ovarian cancer platinum tolerance treatment preparation. Researches prove that the LncRNA LOC730101 is highly expressed in platinum-sensitive ovarian cancer tissues, and the LOC730101 is an ovarian cancer platinum-sensitive marker, so that the expression of the LOC730101 is applied to the detection of the ovarian cancer platinum chemosensitivity and the enhancement of the chemosensitivity of human ovarian cancer platinum drugs through overexpression, and has profound clinical significance and generalization performance.

The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the treatment of EGFR TKI-naive patients with locally-advanced or metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC), wherein the EGFR TKI is administered in combination with pemetrexed and platinum chemotherapy.